Q32 Bio (QTTB) Competitors $2.00 -0.22 (-9.91%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.99 -0.01 (-0.50%) As of 08/1/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. HLVX, IMUX, ZNTL, ANIX, OKYO, ONCY, IPA, CLYM, PLRX, and ABOSShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include HilleVax (HLVX), Immunic (IMUX), Zentalis Pharmaceuticals (ZNTL), Anixa Biosciences (ANIX), OKYO Pharma (OKYO), Oncolytics Biotech (ONCY), ImmunoPrecise Antibodies (IPA), Climb Bio (CLYM), Pliant Therapeutics (PLRX), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Its Competitors HilleVax Immunic Zentalis Pharmaceuticals Anixa Biosciences OKYO Pharma Oncolytics Biotech ImmunoPrecise Antibodies Climb Bio Pliant Therapeutics Acumen Pharmaceuticals Q32 Bio (NASDAQ:QTTB) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment. Is QTTB or HLVX more profitable? HilleVax's return on equity of -51.86% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -447.33% -59.77% HilleVax N/A -51.86%-41.45% Do institutionals & insiders have more ownership in QTTB or HLVX? 31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 86.4% of HilleVax shares are held by institutional investors. 40.0% of Q32 Bio shares are held by insiders. Comparatively, 24.9% of HilleVax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer QTTB or HLVX? In the previous week, Q32 Bio and Q32 Bio both had 1 articles in the media. HilleVax's average media sentiment score of 0.75 beat Q32 Bio's score of -0.50 indicating that HilleVax is being referred to more favorably in the news media. Company Overall Sentiment Q32 Bio Negative HilleVax Positive Do analysts rate QTTB or HLVX? Q32 Bio currently has a consensus target price of $12.17, indicating a potential upside of 508.33%. HilleVax has a consensus target price of $2.00, indicating a potential downside of 1.96%. Given Q32 Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Q32 Bio is more favorable than HilleVax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25HilleVax 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher earnings and valuation, QTTB or HLVX? Q32 Bio has higher revenue and earnings than HilleVax. HilleVax is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio$1.16M21.03-$47.73M-$4.94-0.40HilleVaxN/AN/A-$147.27M-$2.15-0.95 SummaryQ32 Bio beats HilleVax on 7 of the 12 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding QTTB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.40M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.13%P/E Ratio-0.4017.8528.9923.78Price / Sales21.03309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book4.268.488.255.54Net Income-$47.73M-$55.06M$3.25B$259.97M7 Day Performance-9.50%-3.99%-3.75%-4.67%1 Month Performance38.89%8.53%2.99%3.29%1 Year Performance-94.72%6.51%25.34%17.92% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio1.6345 of 5 stars$2.00-9.9%$12.17+508.3%-94.7%$24.40M$1.16M-0.4039Upcoming EarningsShort Interest ↑HLVXHilleVax1.8408 of 5 stars$2.13-0.9%$2.00-6.1%+20.0%$107.80MN/A-0.9920News CoveragePositive NewsIMUXImmunic2.9693 of 5 stars$1.08-3.6%$7.50+594.4%-27.8%$107.32MN/A-0.8870News CoverageUpcoming EarningsGap DownZNTLZentalis Pharmaceuticals2.0981 of 5 stars$1.44-2.0%$8.37+481.0%-62.9%$105.77M$67.43M-0.46160News CoveragePositive NewsUpcoming EarningsANIXAnixa Biosciences3.4105 of 5 stars$3.29+2.2%$9.00+173.6%-8.8%$103.72MN/A-8.665OKYOOKYO Pharma3.1771 of 5 stars$2.73-0.7%$7.00+156.4%+230.5%$103.43MN/A0.007Positive NewsGap UpONCYOncolytics Biotech2.4521 of 5 stars$1.09+3.8%$4.33+297.6%-2.9%$99MN/A-3.7630Upcoming EarningsIPAImmunoPrecise Antibodies2.0224 of 5 stars$2.02-6.5%$4.00+98.0%+94.8%$98.85M$24.00M-1.7480News CoverageEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap UpCLYMClimb Bio2.5195 of 5 stars$1.60+10.3%$9.00+462.5%N/A$97.99MN/A-0.679Positive NewsHigh Trading VolumePLRXPliant Therapeutics3.638 of 5 stars$1.59+1.3%$13.31+737.3%-88.6%$96.38M$1.58M-0.4490Upcoming EarningsABOSAcumen Pharmaceuticals2.5697 of 5 stars$1.46-7.0%$6.33+333.8%-54.8%$95.10MN/A-0.7520Positive News Related Companies and Tools Related Companies HilleVax Competitors Immunic Competitors Zentalis Pharmaceuticals Competitors Anixa Biosciences Competitors OKYO Pharma Competitors Oncolytics Biotech Competitors ImmunoPrecise Antibodies Competitors Climb Bio Competitors Pliant Therapeutics Competitors Acumen Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
